DMD # 68213

INTRODUCTION
Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily catalyze the covalent linkage (conjugation) of glucuronic acid, which is derived from the cofactor UDP-glucuronic acid (UDP-GlcUA), to a typically lipophilic substrate containing a nucleophilic acceptor functional group. Functional groups that are glucuronidated include hydroxyl (aliphatic and phenolic), carboxylic acids, amines (primary, secondary, tertiary and aromatic) and thiols.
Consistent with the ability of UGTs to metabolize compounds containing these commonly occurring functional groups, glucuronidation serves as an elimination and detoxification mechanism for drugs from almost all therapeutic classes, non-drug xenobiotics, endogenous compounds, and the products of oxidative metabolism (Miners and Mackenzie, 1991; Kiang et al., 2005; Miners et al., 2004) . Twenty two human UGT proteins have been identified to date (Mackenzie et al., 2005) . Nineteen of these, classified in the UGT 1A, 2A and 2B subfamilies, primarily utilize UDP-GlcUA as cofactor. Available evidence indicates that the individual UGT enzymes exhibit distinct but sometimes overlapping substrate and inhibitor selectivities 2010a; Rowland et al., 2013) . However, data are lacking for several UGTs, especially with respect to inhibitor profiles. UGT2B10 was cloned initially in this laboratory and demonstrated to lack activity towards hydroxylated xenobiotics and steroids (Jin et al., 1993) . The inability of UGT2B10 to catalyze the O-glucuronidation of these compounds was subsequently shown to arise from substitution of the near conserved His, present in the N-terminus putative substrate binding domain of all UGT family 1 and 2 enzymes except UGT1A4 and UGT2B10, with Leu (Kerdpin et al., 2009) . Substitution of Leu34 of UGT2B10 with His, which functions as the catalytic base in O-glucuronidation reactions, generated an enzyme that metabolized the DMD # 68213 6 Although initially considered an 'orphan' enzyme more recent studies have shown that UGT2B10, like UGT1A4, catalyzes the N-glucuronidation of a number of xenobiotics that incorporate an aliphatic tertiary amine or aromatic N-heterocyclic group (Kaivosaari et al., 2011) . Known substrates are nicotine and its oxidation product cotinine (Kaivosaari et al., 2007; Chen et al., 2007) , desloratadine (Kazmi et al., 2015a) , medetomidine (Kaivosaari et al., 2008) , the tricyclic antidepressants (TCAs) amitriptyline, clomipramine, imipramine and trimipramine (Chen et al., 2007; Zhou et al., 2010; Kato et al., 2013) , several tobacco-specific nitrosamines (Chen et al., 2008) , RO5263397 (Fowler et al., 2015) , and miscellaneous drugs that include diphenhydramine, ketoconazole, ketotifen, midazolam, olanzapine, pizotifen and tamoxifen (Erickson-Ridout et al., 2011; Kato et al., 2013) . Consistent with the known selectivity of UGT1A4 for N-glucuronidation (Kubota et al., 2007) , most if not all UGT2B10 substrates are additionally glucuronidated by UGT1A4 and biphasic kinetics are frequently observed when human liver microsomes (HLM) are used as the enzyme source (Kaivosaari et al., 2011; Kato et al., 2013) . However, available evidence indicates that UGT2B10 is the high affinity enzyme involved in most reactions.
The UGT2B10 substrates desloratadine and nicotine further act as inhibitors of this enzyme. In particular, desloratadine has been reported to be a relatively selective and potent competitive inhibitor of UGT2B10, with a K i of 1.3 µM (Kazmi et al., 2015b) . Nicotine has also been employed as an inhibitor of UGT2B10 in vitro, although the UGT enzyme inhibition selectivity of this compound is incompletely characterized (Zhou et al., 2010) . A large number of clinically used drugs contain an aliphatic amine or aromatic N-heterocyclic group. Notable in this regard are antidepressants (TCAs, selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), tetracyclic antidepressants, and monoamine oxidase inhibitors (MAOIs)) and antipsychotics (both 'typical' and 'atypical') . Indeed, the majority of drugs in these classes are either tertiary or This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 15, 2015 as DOI: 10.1124 at ASPET Journals on August 15, 2017 dmd.aspetjournals.org Downloaded from secondary aliphatic amines. Despite their widespread clinical use, however, the potential inhibition of UGT2B10 by these compounds has not been explored in a systematic manner.
Furthermore, knowledge of the effects of UGT enzyme selective inhibitors employed for reaction phenotyping in vitro on UGT2B10 activity is similarly lacking (Miners et al, 2010) .
Thus, the aims of the present study were to: confirm the UGT enzyme selectivity of cotinine as a UGT2B10 substrate and desloratadine and nicotine as UGT2B10 inhibitors; investigate the potential inhibition of UGT2B10 by currently used UGT enzyme selective inhibitors employed for reaction phenotyping; and characterize the inhibition of UGT2B10 by 34 amine (primary, secondary and tertiary) containing antidepressants and antipsychotics from various classes (TCAs, SSRIs, SNRIs, MAOIs, and typical and atypical antipsychotics).
Data generated from these studies were employed to identify the structural features of compounds required for potent inhibition of UGT2B10 and to provide insights into potential drug-drug interactions (DDIs) arising from inhibition of this enzyme.
DMD # 68213
and base plates were purchased from Thermo Scientific (Rockford, IL). Solvents and other reagents used were of analytical reagent grade.
Methods
HLM and recombinant human UGTs
Approval for the use of human liver tissue for in vitro drug metabolism studies was obtained from the Southern Adelaide Clinical Research Ethics Committee. HLM were activated by pre-incubation with the pore-forming agent alamethicin (50 µg/mg microsomal protein) prior to use in incubations according to Boase and Miners (2002) . Human UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9 and 1A10 cDNAs were stably expressed in a human embryonic kidney cell line (HEK293T) according to Uchaipichat et al (2004) . Cells expressing the individual UGTs were lysed by sonication using a Vibra Cell VCX 130 Ultrasonics Processor (Sonics and Materials, Newtown, CT). The lysates were centrifuged at 12,000 g for 1 min at 4°C, and the supernatant fractions were separated and stored in phosphate buffer (0.1 M, pH 7.4) at -80°C until use. Given the lower expression of UGT 2B4, 2B7, 2B10, 2B15 and 2B17 in HEK293 cells, Supersomes expressing these proteins were used for activity and inhibition studies.
Cotinine N-glucuronidation by recombinant UGTs and HLM
Thirteen recombinant human UGTs were screened for cotinine N-glucuronide formation; UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17.
Incubations (100 µl total volume) contained cotinine (0.25, 1 and 5 mM), Supersome or HEK293 lysate protein (1 mg/ml), 0.1 M phosphate buffer (pH 7.4) and 4 mM MgCl 2 . The incubation mixtures were pre-incubated at 37 °C for 5 min and then reactions were initiated by the addition of 5 mM UDP-GlcUA. Incubations were performed at 37 °C for 120 min, after which time reactions were terminated by the addition of 11.6 M HClO 4 (1 µl). Samples This article has not been copyedited and formatted. The final version may differ from this version. were cooled on ice for 10 min and then centrifuged at 5,000 g, 4 °C for 10 min. An aliquot was injected onto the HPLC column (see below). For the kinetic characterization of cotinine N-glucuronidation by recombinant UGT2B10 and HLM, incubations were conducted as described above for recombinant UGTs and contained either UGT2B10-expressing Supersomes (1 mg/ml) or HLM (0.5 mg/ml). The kinetics of cotinine N-glucuronidation were characterized in the absence and presence of BSA (1% w/v). Incubations containing BSA were terminated by the addition of 3 µL of 11.6 M HClO 4 .
Quantification of cotinine N-glucuronide formation
Cotinine N-glucuronide formation was measured using an Agilent 1200 series (Agilent Technologies, Sydney, Australia) fitted with a Zorbax Eclipse XBD-C8, 4.6 x 150 mm, 5 µm (Agilent Technologies). Cotinine N-glucuronide was eluted by isocratic elution with a 96:4 mixture of mobile phases A (4 mM 1-octanesulfonic acid adjusted to pH 2.7 with 11.6 M HClO 4 ) and B (acetonitrile) at a flow rate of 1 ml/min. Column eluent was monitored at a wavelength of 254 nm. The retention times of cotinine N-glucuronide and cotinine were 7 and 43 min, respectively. Cotinine N-glucuronide was quantified by reference to a calibration curve prepared using an authentic standard. Calibration curve concentration ranges were 1-5 µM and 1-25 µM with UGT2B10 and HLM as the respective enzyme sources.
Inhibition of recombinant human UGT2B10 activity by antidepressants, antipsychotics and other compounds
The inhibition of recombinant human UGT2B10 enzyme activity was determined for 43 compounds (see Results). Effects on UGT2B10 activity were investigated at four inhibitor concentrations (1, 10, 100 and 500 μM), except for fluconazole (1, 2.5, 5 and 10 mM), hecogenin (1, 10, 50 and 100 μM), itraconazole (1, 10, 50, and 100 μM), ketoconazole (1, 10, 
Inhibition of recombinant human UGT enzyme activities by desloratadine and nicotine
In addition to effects on UGT2B10, desloratadine and nicotine (1, 10, 100 and 500 μM) were screened for inhibition of the UGT1A and UGT2B subfamily enzymes UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15 and 2B17. Effects on all enzymes except UGT1A4 and UGT2B4 were determined using the non-selective substrate 4MU. The 4MU concentration used in incubations corresponded to the published apparent K m or S 50 of each enzyme, while protein concentrations and incubation time varied for each enzyme as described by Uchaipichat et al. (2004) . 4MU glucuronide formation was quantified according to Lewis et al. (2007) . Inhibition of UGT1A4 by desloratadine and nicotine was assessed with lamotrigine as the probe substrate following the method of Rowland et al. (2006) , while effects on UGT2B4 activity were determined with codeine as the substrate as described by Raungrut et al. (2010) . Concentrations of lamotrigine and codeine used in the UGT1A4 and UGT2B4 inhibition screening studies corresponded to the respective K m values for each substrate/pair; 1.5 mM for lamotrigine/UGT1A4 and 2.0 mM for codeine/UGT2B4. Positive control inhibitors were used in all inhibition screening experiments, described in Pattanawongsa et al. (2015) . The magnitude of inhibition of each positive control inhibitor (data not shown) was as expected from previous studies in this laboratory (Miners et al., 2011; Raungrut et al., 2010; Uchaipichat et al 2004 Uchaipichat et al , 2006a Uchaipichat et al and 2006b ). Pattanawongsa et al. (2015) . For the assessment of cotinine binding, the sample chamber was loaded with cotinine (0.1 -15 mM) and Supersome protein (1 mg/ml) or HLM (0.5 mg/ml) or BSA (1% w/v), in 0.1 M phosphate buffer (pH 7.4, total volume 100 µl). The buffer chamber was loaded with 300 µl of 0.1 M phosphate buffer (pH 7.4). Experiments were also performed with buffer-buffer, enzyme-enzyme and BSA-BSA controls. The RED devices were incubated at 37 °C for 5 hr, by which time equilibrium had been achieved. A 30 µL aliquot was collected from each chamber and protein was precipitated with 0.3 µl of 11.6 M HClO 4 , or with 0.9 µL of 11.6 M HClO 4 for samples containing BSA. Samples were cooled on ice for 10 min and then centrifuged (5,000 g) at 4 °C for 10 min. A 10 µl aliquot was diluted with 90 µl of 5% acetonitrile in water. Cotinine was analyzed by HPLC following the procedure described for cotinine N-glucuronide, but using 83% mobile phase A and 17% mobile phase B. Under these conditions, the retention time of cotinine was 4.6 min.
The binding of amitriptyline, doxepin and mianserin (2, 5, 10 and 25 µM) to HLM (0.5 mg/ml) plus BSA (1% w/v) was similarly measured using the RED device. Like cotinine, experiments were performed with buffer-buffer and protein-protein controls. After 8 hr equilibration, a 70 µl aliquot was taken from each chamber and mixed with four volumes of 4% acetic acid in methanol, which also contained the assay internal standard (Supplemental Table 1 ). Samples were cooled on ice for 10 min, and then centrifuged (5,000 g) at 4 °C for 10 min. The supernatant fraction was decanted and evaporated to dryness using a miVac modular concentrator (Genevac, Suffolk, UK). The residue was reconstituted in 50 µL of the mobile phase and analyzed by HPLC (see Supplemental Table 1 for conditions).
Molecular modelling
The three-dimensional (3D) coordinates (sdf format) of dataset molecules were obtained from the Pubchem server (https://pubchem.ncbi.nlm.nih.gov/). The molecules were imported into This article has not been copyedited and formatted. The final version may differ from this version. SYBYL (version X-2.1, CERTARA, Princeton, NJ) and geometry optimized using the AM1 Hamiltonian (MOPAC). All molecular modelling was performed using SYBYL installed on Macintosh workstation running on OS X 10.9.5 operating system. The structural overlay of molecules was undertaken using the Surflex-Sim program (Jain 2000 and 2004) , which utilizes the morphological similarity approach to generate alignments of molecules.
Similarity is defined as a Gaussian function of the differences in the molecular surface distances of two molecules at weighted observation points on a uniform grid. The computed surface represent distances to the nearest atomic surface and distances to donor and acceptor surfaces. Amitriptyline, one of the most potent UGT2B10 inhibitors (see Results), was used as the template for the overlay of dataset molecules. The overlay quality of the dataset molecules was evaluated by measuring the distance between key pharmacophoric features, including the centroid of either of the phenyl rings (present in the tricyclic structure of amitriptyline) and the aryl ring (closest) of the dataset molecule observed in the alignment.
Moreover, the distances between the side-chain amine N atom of amitriptyline and the dataset molecules (aliphatic or alicyclic) were also estimated. The smaller the distance, the more closely the pharmacophoric features overlay between amitriptyline and the dataset molecule.
In addition, for tri-and tetra-cyclic compounds, the angles between the rings of the tricyclic scaffold were measured by defining a centroid for each ring on the geometry optimized structures. The torsion angles were measured for the bridge (-CH 2 -X where X= -CH 2 , -O, or -N) connecting the two aromatic rings of the tricyclic scaffold. For example, in the case of amitriptyline the torsion angle was measured for the dimethylene (-CH 2 -CH 2 -) bridge of the central 7-membered (cycloheptene) ring.
Data Analysis
The Michaelis-Menten equation (equation 1) was fit to kinetic data for cotinine Nglucuronidation by UGT2B10 and HLM (± 1% BSA) using Enzfitter (version 2.0, Biosoft, This article has not been copyedited and formatted. The final version may differ from this version. 
where v is the rate of product formation, V max is maximal velocity, [S] is substrate concentration and K m is the Michaelis constant.
Equation 2, competitive inhibition:
where [I] is the inhibitor concentration and K i is the inhibitor constant (for the EI complex).
where K i is the inhibitor constant for the EI and ESI complexes. 
where K i and K i ' are the inhibitor constants for the EI and ESI complexes, respectively. (Virtanen et al., 1980) , fu 0.79 (Faulkner et al., 1983) . Again, assuming linear kinetics, the C max expected for a single 150 mg dose of doxepin is 0.87 µM. Mianserin (60 mg dose): mean C max 0.38 µM (Hrdina et al., 1983) , fu 0.055 (Kristensen et al., 1985) .
Statistical comparisons of kinetic constants reported in Table 1 were performed using the Mann-Whitney U-test with SPSS version 22 (SPSS Inc, Chicago, IL). P values < 0.05 were considered significant.
This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Kinetics of cotinine N-glucuronidation
Cotinine N-glucuronidation by recombinant UGT2B10 and HLM (± BSA, 1% w/v) followed Michaelis-Menten kinetics (Figure 1) . Mean (± SD) kinetic constants are given in Table 1 .
The mean K m for human liver microsomal cotinine N-glucuronidation was marginally higher (p = 0.06) than that for UGT2B10, while the V max with HLM as the enzyme source was 6.8-fold higher compared to UGT2B10. The activities of numerous UGTs, particularly with HLM as the enzyme source, are known to be increased in the presence of BSA (0.5 -2% w/v) due to sequestration of inhibitory membrane long-chain unsaturated fatty acids released during the course of an incubation (Rowland et al., 2007 and Manevski et al., 2011; Kilford et al., 2009; Walsky et al., 2012) . Nicotine and desloratadine (1, 10, 100 and 500 µM) were screened for inhibition of UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15 and 2B17. Over the concentration range investigated, nicotine inhibited only UGT2B10 with an IC 50 < 500 µM ( Figure 2A) ; the mean (± standard error of parameter fit) IC 50 value was 214 ± 2.9 µM.
Consistent with the recent report of Kazmi et al. (2015b) , desloratadine potently inhibited UGT2B10 (IC 50 3.86 ± 0.05 µM). IC 50 values for other hepatically expressed UGT enzymes ranged from 18.9 ± 0.10 µM for UGT2B4 to 271 ± 7.6 µM for UGT1A6 ( Figure 2B and Supplemental Table 2 ). In general, the inhibition observed here for desloratadine (10 µM) is in good agreement to that reported by Kazmi et al. (2015b) for hepatically expressed UGT enzymes, except UGT2B4 which was not investigated by these authors.
Inhibition of recombinant UGT2B10 by UGT enzyme-selective inhibitors
Effects of putative UGT enzyme selective inhibitors on recombinant UGT2B10 activity were assessed using cotinine as the substrate probe. The UGT1A4 inhibitor hecogenin (1 -100 µM) was without effect on UGT2B10 activity (Table 2) , consistent with the observations of Guo et al. (2011) and Kato et al. (2013) . Niflumic acid, which inhibits UGT1A9 with a K i of 0.10 µM and UGT1A1 and UGT2B15 with respective K i 's of 18 and 62 µM (Miners et al., 2011) , inhibited UGT2B10 with an IC 50 of 168 ± 0.14 µM (Table 2) . Fluconazole, employed as a selective inhibitor of UGT2B4 and UGT2B7 (Uchaipichat et al., 2006b; Raungrut et al., 2010) , inhibited UGT2B10 with an IC 50 of 1136 ± 88.4 µM (Table 2) , while phenylbutazone, which has been reported to be a relatively selective inhibitor of UGT1A subfamily enzyme activities (Uchaipichat et al., 2006a) antifungal agents, itraconazole and ketoconazole. Whereas itraconazole was without effect on UGT2B10, ketoconazole was a relatively potent inhibitor of this enzyme (IC 50 = 11.9 ± 1.7 µM; Table 2 ).
The contribution of UGT2B10 to human liver microsomal cotinine N-glucuronidation
As shown above, of the hepatically expressed enzymes in the UGT 1A and 2B subfamilies only UGT1A4 and UGT2B10 glucuronidated cotinine. Inhibition studies with hecogenin and desloratadine were performed to elucidate the relative contributions of these enzymes to human liver microsomal cotinine N-glucuronidation. Effects of desloratadine and hecogenin (both 10 µM), separately and combined, were determined at four cotinine concentrations that spanned the K m for cotinine N-glucuronidation by HLM (viz. 0.25, 1, 3 and 6 mM).
Hecogenin had a negligible effect (< 10% inhibition) at all cotinine concentrations (Figure 3 ).
By contrast, desloratadine, alone and in combination with hecogenin, inhibited human liver microsomal cotinine N-glucuronidation to a near identical extent (Figure 3 ). It should be noted that the extent of cotinine N-glucuronidation observed with 10 µM desloratadine is broadly consistent with IC 50 for desloratadine (ca. 4 µM) reported in Table 2 . Consistent with competitive inhibition by desloratadine (Kazmi et al., 2015b) , greater and lesser inhibition occurred at cotinine concentrations below and above the K m , respectively. Collectively, the data indicate that cotinine is a selective substrate of human liver microsomal UGT2B10.
Inhibition of recombinant UGT2B10 by antidepressant and antipsychotic drugs: modelling and structure-activity relationships
Thirty four antidepressant drugs (including didesmethylimipramine and desmethylnortriptyline, the respective demethylated metabolites of desipramine and nortriptyline) were screened as potential inhibitors of UGT2B10 ( Ligand-based approaches were employed to identify the structural features associated with significant inhibition. The majority of significant inhibitors (arbitrarily defined as having an IC 50 < 100 µM) are generally tri-or tetra-cyclic structures with an amine-containing sidechain (aliphatic or alicyclic), although exceptions occur. All of the tricylic and tetracyclic compounds, except olanzapine, overlaid well on the structure of amitriptyline ( Figure 4A -C).
Olanzapine is the only compound investigated here with a 5-membered ring in the tricyclic scaffold, which results in a different geometry and poor overlay (Supplemental Figure 2) . The bis-ring structure of fluoxetine permits adoption of a conformation similar to that of amitriptyline, resulting in a reasonable overlay. Of the bicyclic compounds that exhibited significant inhibition, aripiprazole, duloxetine and paroxetine aligned reasonably well with the structure of amitriptyline (Supplemental Figure 2 ) whereas partial overlay was observed for sertraline (IC 50 92.7 µM), presumably due to the shorter distance between the ring scaffold and side-chain amine group. Poor overlay of the SSRIs citalopram and fluvoxamine, including the side-chain amine of the latter (which aligns 3.3 Å from the side-chain N of amitriptyline) provides an explanation for the weak inhibition observed with these compounds. Overlay on the structure of amitriptyline for the remaining compounds screened for inhibition (viz. haloperidol, venlafaxine, desvenlafaxine and the MAOIs phenelzine, selegiline and tranylcypromine), all of which lack a fused ring scaffold, was generally consistent with the observed potency of UGT2B10 inhibition (Supplemental Figure 2 ).
Compared to other TCAs, the potent UGT2B10 inhibitors amitriptyline and doxepin share in common a side-chain tertiary amine functional group linked to the central cycloheptene ring by a double bond rather than to a potentially invertible N atom (Supplemental Figure 1) . The exocyclic double bond present in loratadine and desloratadine, and the fused piperidine ring present in mianserin similarly confer structural rigidity. Near identical geometries were observed for amitriptyline, doxepin, desloratadine and loratadine, and consequently there was near complete overlap of structural features ( Figure 5A ). By contrast, conformational differences occur around the CH 2 -X moiety of the cycloheptene ring of other TCAs (e.g. imipramine), and the ring scaffold of tricyclic compounds with a 6-membered central ring (e.g. chlorpromazine) is more planar (Figure 5B and C).
The kinetics of amitriptyline, doxepin and mianserin inhibition of human liver microsomal
UGT2B10 and in vitro -in vivo extrapolation
Given the potent inhibition of UGT2B10 observed for amitriptyline, doxepin and mianserin, 
DISCUSSION
Initial studies confirmed that cotinine is a selective substrate for UGT2B10, and desloratadine and nicotine are relatively selective inhibitors of this enzyme. Cotinine N-glucuronidation by HLM followed Michaelis-Menten kinetics, consistent with the predominant involvement of a single UGT enzyme in this reaction. It has been reported previously that only UGT 1A4 and 2B10 glucuronidate cotinine (Kuehl and Murphy, 2003; Kaivosaari et al., 2007) . This was confirmed here, although the cotinine N-glucuronidation activity of UGT1A4 was very low.
To further elucidate the relative contributions of UGT2B10 and UGT1A4 to human liver microsomal cotinine N-glucuronidation, inhibition experiments were conducted with desloratadine and the UGT1A4 selective inhibitor hecogenin (Uchaipichat et al., 2006a) . The separate and combined effects of desloratadine and hecogenin shown in Figure 3 demonstrate that UGT2B10 is responsible for > 90% of cotinine N-glucuronidation by HLM, making this compound a convenient, readily available UGT2B10 substrate probe. Moreover, compared to many other UGT enzyme selective substrate probes, cotinine does not bind to BSA (or HLM) and hence correction for non-specific and protein binding is not required.
Consistent with the recent report of Kazmi et al. (2015b) , desloratadine was shown to be a moderately selective inhibitor of UGT2B10 ( Figure 2B ). The IC 50 for UGT2B10
inhibition is approximately an order of magnitude lower than that for UGT2B4, the next most potently inhibited enzyme. UGT2B4 was not screened for inhibition in the study of Kazmi et al. (2015b) . Thus, it may not be possible to differentiate relative contributions of UGT2B10 and UGT2B4 when desloratadine (10 µM; Kazmi et al., 2015b) is used for reaction phenotyping. Previous studies have reported that nicotine inhibits UGT2B10 but not UGT1A4 (Zhou et al., 2010) . Similar specificity was observed here, although nicotine was observed to additionally inhibit UGT2B15, albeit less potently than UGT2B10.
This article has not been copyedited and formatted. The final version may differ from this version. have found that the UGT2B10 activity of Supersomes remains stable for at least 6 months.
The addition of BSA (0.5 -2% w/v) to incubations has been reported to decrease the K m values (with occasional effects on V max ) for substrates of several hepatically expressed UGT enzymes, particularly UGT 1A9, 2B4, 2B7 and 2B15 (Rowland et al., 2007 and Manevski et al., 2011 and Kilford et al., 2009; Walsky et al., 2012) . The 'albumin effect' appears to arise from sequestration of inhibitory membrane fatty acids released during the course of an incubation. The effect of lower concentrations of BSA has been reported to be substrate dependent (Manevski et al., 2013) , but this may arise from incomplete sequestration of inhibitory fatty acids at BSA concentrations < 0.5% w/v. Addition of BSA (1% wv) was found here to reduce the K m for human liver microsomal nicotine Nglucuronidation by approximately 50%, with a small (11%) but statistically significant This article has not been copyedited and formatted. The final version may differ from this version. UGT enzyme-selective inhibitors are a valuable experimental tool for the reaction phenotyping of human liver microsomal drug and chemical glucuronidation (Miners et al., 2010) . However, previous studies that have characterised UGT enzyme inhibition selectivity have generally excluded UGT2B10. Niflumic acid at a concentration of 2.5 µM is considered a highly selective inhibitor of UGT1A9 (Miners et al., 2011) , whereas at 100 µM it additionally inhibits UGT1A1 and UGT2B15. The IC 50 for niflumic acid inhibition of UGT2B10 observed here (168 µM) confirms the UGT1A9 inhibition selectivity of niflumic acid at a low concentration, but indicates that this compound will significantly inhibit UGT2B10 as well as UGT1A1 and UGT2B15 at a concentration of 100 µM. As noted above, hecogenin does not inhibit UGT2B10 consistent with the reported inhibition selectivity for UGT1A4 (Uchaipichat et al., 2006b) . By contrast, fluconazole (2.5 mM), which is considered a selective inhibitor of UGT2B4 and UGT2B7, inhibited UGT2B10 to a similar extent to that reported for UGT2B4/7 (Raungrut et al., 2010; Uchaipichat et al., 2006a) . The latter observation prompted us to investigate UGT2B10 inhibition by two additional azole antifungals; itraconazole and ketoconazole. While the triazole itraconazole was without effect on UGT2B10, the imidazole ketoconazole was a relatively potently inhibitor of this enzyme (IC 50 = 11.9 ± 1.7 µM). Similar to the inhibition selectivity of fluconazole, ketoconazole has previously been reported to be a relatively potent inhibitor of UGT2B4 (Raungrut et al., 2010) and an inhibitor of UGT2B7 (Takeda et al., 2006) .
Previous studies have shown that the TCAs amitriptyline, clomipramine, imipramine and trimipramine, and the atypical antipsychotic olanzapine are substrates and/or inhibitors of UGT2B10 (Chen et al., 2007; Zhou et al., 2010; Guo eta l., 2011; Kato et al., 2013) . As However, the presence of a tertiary amine is not an obligatory requirement for inhibition; moderate inhibition occurred with primary and secondary amines. Since the amines will be largely charged at physiological pH, the data suggest that hydrophobic and charge interactions (e.g. with aspartic or glutamic acid) are involved in inhibitor binding.
The data also suggest that spatial features influence the potency of UGT2B10
inhibition. TCAs with a dihydrodibenzazepine moiety (e.g. clomipramine, desipramine and imipramine) are inherently more flexible with more degrees of conformational freedom than dibenzocycloheptenes such as amitriptyline and doxepin. It has been proposed that such conformational differences, particularly in the tricyclic ring scaffold, may be associated with differences in the receptor binding selectivity and affinity of TCAs (Casarotto and Craik, 2001; Munro et al., 1987 ). As noted above and shown in Figures 5A-C , the relatively subtle conformational differences noted between amitriptyline, doxepin, desloratadine and loratadine compared to other TCAs (e.g. imipramine) and tricyclic compounds with a 6-This article has not been copyedited and formatted. The final version may differ from this version. (Rowland et al., 2006; Raungrut et al., 2010; Pattanawongsa et al., 2015) , prediction of DDI potential from in vitro data for drugs cleared by glucuronidation appears to be more accurate when [I] is taken as total drug concentration, despite the fact that unbound concentration in blood is expected to reflect the hepatocellular concentration. Based on the reported K i for desloratadine (ca. 1 µM), Kazmi et al. (2015b) predicted a 2.2-fold increase in the AUC-ratio for UGT2B10 substrates, which is similar to that proposed here for amitriptyline, doxepin and mianserin. It is noteworthy that few compounds appear to be solely metabolized by UGT2B10, although the clearance of the experimental antipsychotic agent RO5263397 appears to be mediated largely by UGT2B10 (Fowler et al., 2015) .
The potent inhibition of UGT2B10 by several drugs observed here is consistent with previous reports from this laboratory demonstrating that inhibition of other UGT enzymes (e.g. UGT 1A1, 1A9, 2B4 and 2B7) may potentially precipitate DDIs and drug-endobiotic interactions (Boyd et al., 2006; Miners et al., 2010b; Pattanawongsa et al., 2015; Raungrut et al., 2010; Uchaipichat et al., 2006b This article has not been copyedited and formatted. The final version may differ from this version. 
